Literature DB >> 29183246

Uptake trends in the Scottish Bowel Screening Programme and the influences of age, sex, and deprivation.

Aaron J Quyn1, Callum G Fraser1, Greig Stanners2, Francis A Carey3, Claire Carden1, Aasma Shaukat4, Robert Jc Steele1.   

Abstract

Objective Age, sex, and deprivation are known factors influencing colorectal (bowel) cancer screening uptake. We investigated the influence of these factors on uptake over time. Methods Data from the Scottish Bowel Screening Programme (SBoSP) were collected between 2007 and 2014. End-points for analysis were uptake, faecal occult blood test positivity, and disease detection, adjusted for age, sex, deprivation, and year of screening. Results From 5,308,336 individual screening episodes documented, uptake gradually increased with increasing age up to 65-69 and was lower in men than women (52.4% vs. 58.7%, respectively). Deprivation had a significant effect on uptake by men and women of all age groups, with the most deprived least likely to complete a screening test. Uptake has increased with time in both sexes and across the deprivation gradient. The number needed to screen to detect significant neoplasia was significantly lower in men than women overall (170 vs. 365), and this held over all age and deprivation groups. The number needed to screen was also lower in the more deprived population. Conclusions Although lower age, male sex, and increased deprivation are associated with lower bowel cancer screening uptake in Scotland, uptake has increased since SBoSP introduction in all age groups, both sexes, and across the deprivation gradient. Despite a lower uptake, the number needed to screen to find significant disease was lower in men and in those with higher levels of deprivation.

Entities:  

Keywords:  Bowel screening; age; colorectal cancer; deprivation; faecal occult blood test; trends

Mesh:

Year:  2017        PMID: 29183246     DOI: 10.1177/0969141317694065

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  6 in total

1.  The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.

Authors:  Chloe Thomas; Olena Mandrik; Catherine L Saunders; Deborah Thompson; Sophie Whyte; Simon Griffin; Juliet A Usher-Smith
Journal:  Cancer Prev Res (Phila)       Date:  2021-05-26

2.  A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK.

Authors:  Alan White; Lucy Ironmonger; Robert J C Steele; Nick Ormiston-Smith; Carina Crawford; Amanda Seims
Journal:  BMC Cancer       Date:  2018-09-20       Impact factor: 4.430

3.  Uptake of the English Bowel (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out.

Authors:  Yasemin Hirst; Sandro Stoffel; Gianluca Baio; Lesley McGregor; Christian von Wagner
Journal:  Eur J Cancer       Date:  2018-09-07       Impact factor: 9.162

4.  Impact of introducing a faecal immunochemical test (FIT) for haemoglobin into primary care on the outcome of patients with new bowel symptoms: a prospective cohort study.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Rebecca McCann; Christopher Hall; Duncan Heather; Francis Carey; Callum G Fraser; Robert J C Steele
Journal:  BMJ Open Gastroenterol       Date:  2019-05-04

5.  Are there ethnic and religious variations in uptake of bowel cancer screening? A retrospective cohort study among 1.7 million people in Scotland.

Authors:  Christine Campbell; Anne Douglas; Linda Williams; Geneviève Cezard; David H Brewster; Duncan Buchanan; Kathryn Robb; Greig Stanners; David Weller; Robert Jc Steele; Markus Steiner; Raj Bhopal
Journal:  BMJ Open       Date:  2020-10-07       Impact factor: 2.692

6.  Psychological correlates of free colorectal cancer screening uptake in a Scottish sample: a cross-sectional observational study.

Authors:  Ronan E O'Carroll; Ian J Deary; Chloe Fawns-Ritchie; Christopher B Miller; Marjon van der Pol; Elaine Douglas; David Bell
Journal:  BMJ Open       Date:  2022-02-01       Impact factor: 3.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.